Genevieve A Losonsky
Overview
Explore the profile of Genevieve A Losonsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anderson E, Simoes E, Buttery J, Dennehy P, Domachowske J, Jensen K, et al.
J Pediatric Infect Dis Soc
. 2015 Dec;
1(3):212-22.
PMID: 26619409
Background: Human metapneumovirus (HMPV) is a significant cause of respiratory tract infections. Little is known about HMPV in children who are at high risk for lower respiratory tract infection (LRTI)....
2.
OBrien K, Chandran A, Weatherholtz R, Jafri H, Griffin M, Bellamy T, et al.
Lancet Infect Dis
. 2015 Oct;
15(12):1398-408.
PMID: 26511956
Background: Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in children. We aimed to assess the safety and efficacy of an anti-RSV monoclonal antibody...
3.
Robbie G, Makari D, Harris B, Losonsky G, Jafri H
Infect Dis Ther
. 2014 Oct;
3(2):203-14.
PMID: 25269648
Objective: To assess the pharmacokinetics and safety of liquid palivizumab compared with lyophilized palivizumab. Methods: This phase 2, randomized, double-blind crossover study included premature infants aged ≤6 months born ≤35 ...
4.
Ramilo O, Lagos R, Saez-Llorens X, Suzich J, Wang C, Jensen K, et al.
Pediatr Infect Dis J
. 2013 Dec;
33(7):703-9.
PMID: 24356256
Background: This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal antibody, would decrease viral load and improve clinical outcomes in previously healthy term...
5.
Robbie G, Criste R, DallAcqua W, Jensen K, Patel N, Losonsky G, et al.
Antimicrob Agents Chemother
. 2013 Oct;
57(12):6147-53.
PMID: 24080653
The study objective was to evaluate the pharmacokinetics (PK), antidrug antibody (ADA), and safety of motavizumab-YTE (motavizumab with amino acid substitutions M252Y/S254T/T256E [YTE]), an Fc-modified anti-respiratory syncytial virus (RSV) monoclonal...
6.
Feltes T, Sondheimer H, Tulloh R, Harris B, Jensen K, Losonsky G, et al.
Pediatr Res
. 2011 Apr;
70(2):186-91.
PMID: 21522037
Children with hemodynamically significant congenital heart disease (CHD) are at risk for serious respiratory syncytial virus (RSV) disease. This study was designed to assess the safety and tolerability of motavizumab...
7.
Zhu Q, McAuliffe J, Patel N, Palmer-Hill F, Yang C, Liang B, et al.
J Infect Dis
. 2011 Jan;
203(5):674-82.
PMID: 21208913
Background: Palivizumab is a US Food and Drug Administration-approved monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory disease in high-risk infants. Motavizumab, derived from palivizumab with...
8.
Fernandez P, Trenholme A, Abarca K, Griffin M, Hultquist M, Harris B, et al.
BMC Pediatr
. 2010 Jun;
10:38.
PMID: 20525274
Background: Respiratory syncytial virus (RSV) is an important pathogen causing annual epidemics of bronchiolitis and pneumonia among infants worldwide. High-risk infants currently receive RSV prophylaxis with palivizumab, a humanized RSV...
9.
Carbonell-Estrany X, Simoes E, Dagan R, Hall C, Harris B, Hultquist M, et al.
Pediatrics
. 2009 Dec;
125(1):e35-51.
PMID: 20008423
Objective: Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal...
10.
Lagos R, DeVincenzo J, Munoz A, Hultquist M, Suzich J, Connor E, et al.
Pediatr Infect Dis J
. 2009 Jul;
28(9):835-7.
PMID: 19636278
Previously healthy children hospitalized with respiratory syncytial virus (RSV) received motavizumab (3, 15, or 30 mg/kg intravenously), an RSV-specific monoclonal antibody, or placebo. Safety, tolerability, motavizumab concentrations, and immunogenicity were...